New eczema drug shows promise in early trial

NCT ID NCT04643457

Completed Symptom relief Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The goal was to check its safety and see if it can improve eczema symptoms. The trial involved 107 participants and compared the drug to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UCB9741
What this could lead to: If it works, this could lead to a new treatment option for people with moderate-to-severe eczema.
What could go wrong: This is an early-phase trial with only 107 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Up0089 101

London, United Kingdom
Up0089 103

Manchester, United Kingdom
Up0089 104

Liverpool, United Kingdom
Up0089 201

Leiden, Netherlands
Up0089 301

Sofia, Bulgaria
Up0089 303

Pleven, Bulgaria
Up0089 304

Sofia, Bulgaria
Up0089 407

Berlin, Germany
Up0089 408

Heidelberg, Germany
Up0089 410

Leipzig, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.